Compare Quest Diagnostics Inc (DGX) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Thomson Reuters Corp — how do they compare? Quest Diagnostics Inc trades at $231.19 (market cap $25.48B), while Thomson Reuters Corp trades at $101.52 (market cap $43.89B). The key difference: Thomson Reuters Corp is the larger of the two by market cap, and Thomson Reuters Corp pays the higher dividend (2.58%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Thomson Reuters Corp for 63 Days on average.
| DGX | TRI | |
|---|---|---|
Market Cap | $25.48B | $43.89B |
Volume | 941,866 | 1,648,199 |
Sector | Health | Industrials |
52-Week High | $247.45 | $163.45 |
52-Week Low | $173.49 | $76.55 |
Typical Hold Time | 56 Days | 63 Days |
Enterprise Value | $31.23B | $46.51B |
Dividend Yield | 1.49% | 2.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% with a bearish technical signal. The company shows strong fundamentals with three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.0B in 2025. Recent developments include positive clinical study results and a new Apple Health integration, though Medicare reimbursement cuts pose headwinds. The stock trades near support at $226 with oversold RSI readings suggesting potential for near-term bounce.
DGX presents a mixed outlook with solid execution offset by regulatory risks. The 10% upside to consensus price target of $250 offers opportunity, but Medicare payment reductions and rising debt levels require monitoring. Recent earnings momentum and strategic partnerships support growth, making DGX suitable for investors comfortable with healthcare sector volatility.
Thomson Reuters (TRI) trades at $101.52, up 2.26% today, with bullish technical signals and strong analyst support. The company shows solid fundamentals with 10% organic growth in core businesses and a 21.22% net income margin. Recent strategic moves include divesting its printing unit and launching a proprietary AI model, positioning TRI for tech-focused growth. Cash flow trends show operational strength despite recent negative net cash flow due to strategic investments.
TRI presents a compelling investment case with analyst consensus target of $133.25 (31% upside), supported by recurring revenue growth and AI expansion. Risks include cybersecurity incidents and execution challenges in tech transformation. The stock's current valuation at 26.75 P/E appears reasonable given growth prospects, making it attractive for long-term investors seeking exposure to content and technology services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
